Dr. Uma Mahadevan is an internationally renowned gastroenterologist and clinical scientist specializing in inflammatory bowel disease (IBD), particularly pregnancy and drug safety. She completed a medical degree at the State University of New York in Brooklyn, residency in internal medicine at Mount Sinai Medical Center in New York, and a fellowship in gastroenterology at the University of California, San Francisco (UCSF). She did an advanced fellowship in IBD at the Mayo Clinic, in Rochester, Minnesota. Dr. Mahadevan currently serves as Professor of Medicine at UCSF, Director of the UCSF Colitis and Crohn’s Disease Center, and Director of the Advanced IBD Fellowship.
Certified by the American Board of Internal Medicine as a Diplomate in internal medicine and gastroenterology, Dr. Mahadevan is a fellow of the American Gastroenterological Association, for whom she was Chair for the Clinical Immunology, Microbiology and Inflammatory Bowel Disease (IMIBD) Section, Chair of the AGA National IBD Parenthood initiative and Director (2023) and co-Director (2022, 2017) of the AGA Postgraduate Course. She is a Fellow of the American College of Gastroenterology and served on the Educational Affairs Committee and as a member of the Advanced IBD Fellow Curriculum Committee. She was Chair of the Crohn’s & Colitis Foundation Clinical Research Grants committee, a member of the National Scientific Advisory Committee and Taskforce on Women in IBD, and co-chair of the annual Crohn’s Colitis Congress (2020). She is the recipient of the AGA 2022 Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) Section Research Mentor Award.
Dr. Mahadevan has served on many prestigious journals, including special section editor for Gastroenterology. Dr. Mahadevan has published over 100 original articles, abstracts, editorials, and invited reviews in such peer-reviewed journals as Gastroenterology, Gut, Nature Reviews, American Journal of Gastroenterology, Inflammatory Bowel Diseases, and Lancet Gastroenterology Hepatology as well as several book chapters. She authored the joint AGA, Society of Maternal Fetal Medicine Clinical Care Pathway on the Management of IBD in Pregnancy.
Dr. Mahadevan specializes in the treatment of complex ulcerative colitis and Crohn’s disease. She is a global expert on the management of pregnancy and drug safety in the patient with IBD. She is also interested in the role of diet and IBD and has an ongoing original study in this area. Her current projects include a national prospective registry of pregnancy outcomes and drug safety in women with IBD on immunosuppressive and biologic medications (PIANO), clinical trials in biologic therapy for IBD, and the impact of nutritional interventions in the management of IBD (SEAMUS). She has an interest in digital health and led the transition of the GI Division to telemedicine at the start of the pandemic in March 2020 and has developed an IBD Chatbot with the Center for Digital Health and Innovation at UCSF. This IBD Chat can remotely monitor thousands of patients with IBD and integrate with the existing electronic health record. Additionally, in collaboration with data scientists at UCSF, she is studying ways to answer important questions in IBD using the UCSF electronic health record.
Dr. Mahadevan is proud to have mentored several Advanced IBD Fellows who now hold key roles in IBD Centers around the United States.
In 2022, Dr. Mahadevan received the Sherman Prize for Excellence in Crohn’s and Colitis.
